Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma

Maria Apellaniz-Ruiz, Meta H. Diekstra, Juan M. Roldan, Epie Boven, Daniel Castellano, Hans Gelderblom, Ron H. J. Mathijssen, Jesse J. Swen, Stefan Bohringer, Jesus Garcia-Donas, Brian I. Rini, Henk-Jan Guchelaar, Cristina Rodriguez-Antona*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)227-231
Number of pages5
JournalPharmacogenetics and Genomics
Volume27
Issue number6
DOIs
Publication statusPublished - Jun 2017

Keywords

  • advanced renal cell carcinoma
  • KDR
  • polymorphism
  • sunitinib
  • vascular endothelial growth factor receptor 2
  • SINGLE-NUCLEOTIDE POLYMORPHISMS
  • 1ST-LINE SUNITINIB
  • INDUCED TOXICITY
  • MARKERS
  • THERAPY
  • VEGFR2
  • IDENTIFICATION
  • HYPERTENSION
  • ASSOCIATION
  • PAZOPANIB

Cite this

Apellaniz-Ruiz, M., Diekstra, M. H., Roldan, J. M., Boven, E., Castellano, D., Gelderblom, H., Mathijssen, R. H. J., Swen, J. J., Bohringer, S., Garcia-Donas, J., Rini, B. I., Guchelaar, H-J., & Rodriguez-Antona, C. (2017). Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. Pharmacogenetics and Genomics, 27(6), 227-231. https://doi.org/10.1097/FPC.0000000000000280